New anti-hepatitis B drug to make debut in December
Published: 2006-08-02 07:00:00
Updated: 2006-08-02 07:00:00
The Korea Food and Drug Administration (KFDA) approved a local pharmaceutical company's anti-hepatitis B drug on July 28 and the market for anti-hepatits B medicines dominated by imported drugs is expected to enter fierce competition.
We have approved Bukwang Pharm's Levovir capsule (clevudine...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
